DDistillerSR provides a SaaS platform that automates evidence-based literature reviews for health technology assessments, regulatory submissions, and post-market surveillance. The product manages literature collection, screening, data extraction, and reporting, using AI-enabled screening to prioritize relevant references, AI audits to catch missed items, and configurable workflows and reporting (including PRISMA diagrams), with integrations to PubMed and Embase and support for very large projects. The platform stands out by offering highly configurable, scalable workflows and AI-assisted automation tailored to life sciences, regulatory, and academic clients, serving many of the world’s largest pharmaceutical and medical device companies along with CROs, governments, and universities. Its goal is to shorten review times and streamline evidence synthesis to support faster, more informed healthcare decisions.
Work here?Claim your company
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$15.6M
Headquarters
Ottawa, Canada
Founded
2008
See people who can refer or advise you
Total Funding
$15.6M
Above
Industry Average
Funded Over
2 Rounds
DistillerSR has launched Smart Screening, a regulatory-grade AI tool for automated title and abstract screening within its evidence management platform. The feature enables pharmaceutical and medical device research teams to screen large volumes of abstracts automatically whilst maintaining full auditability and human oversight. Smart Screening uses the same GenAI technology as DistillerSR's Smart Evidence Extraction module. In a baseline pilot study by Philips, it achieved 90.1% average accuracy before prompt optimisation. The tool can batch-process up to 100,000 abstracts per run. Key capabilities include fully automated workflows with audit trails, human-in-the-loop options for regulatory submissions, and secondary AI error checking. The system requires no model training and works within existing DistillerSR configurations. Over 80% of the world's largest pharmaceutical and medical device companies use DistillerSR for literature review automation.
DistillerSR, a market leader in AI-enabled literature review automation, has launched enhanced generative AI capabilities for its Smart Evidence Extraction module. The system automates end-to-end workflows for extracting evidence from scientific literature whilst maintaining full auditability and human oversight. New features include full form automation, enhanced accuracy with an 8.3 percentage point improvement on the LitQA benchmark, contextual processing across entire extraction forms, and explainable AI with plain-language justifications. The platform includes real-time monitoring via an AI Dashboard and adheres to NIST AI Risk Management Framework standards. The development is part of a three-year research consortium led by DistillerSR involving Philips Medical Systems, University of Leiden Medical Center and others across six countries. DistillerSR serves over 80% of the largest pharmaceutical and medical device companies globally.
DistillerSR, a leader in AI-enabled literature review automation software, has launched DistillerSR Library Services, offering research teams subscription-based access to senior medical librarians for regulatory submissions. The service provides validated, reproducible search strategies using Peer Review of Electronic Search Strategies (PRESS) compliant methodologies. The offering addresses resource constraints in life sciences organisations developing defensible literature search strategies that meet regulatory standards. Rather than hiring full-time librarians, organisations can access fractional services as needed, working directly within the DistillerSR platform. DistillerSR serves over 80% of the largest pharmaceutical and medical device companies, along with contract research organisations, governments, NGOs and academic institutions. CEO Peter O'Blenis said the flexible model accelerates time to regulatory submission whilst maintaining quality standards and managing costs.
OTTAWA, ON / ACCESS Newswire / April 16, 2025 / DistillerSR® Inc., the market leader in AI-enabled literature review automation and evidence management, and creator of DistillerSR®, today announced that it has achieved a Bronze Medal rating from EcoVadis, a global leader in business sustainability standard assessments. The rating recognizes DistillerSR among the top 35% of global organizations and top 19% within its industry as rated by EcoVadis on its 21 sustainability criteria across four themes. These include Environment, Labor & Human Rights, Ethics and Sustainable Procurement. More than 130,000 companies globally have been rated by EcoVadis.DistillerSR Logo"Many medical device and pharmaceutical companies are now applying business sustainability criteria to the vendor selection and validation process," said Peter O'Blenis, CEO, DistillerSR Inc. "Our Bronze Medal rating demonstrates our continued commitment to sustainability as a critical business practice. It also reinforces our much broader continuous security, privacy, quality assurance, and AI risk management compliance program
Evidence Partners, developer of AI-enabled literature review automation software and creator of DistillerSR, has closed a $20 million growth financing round led by Thomvest Ventures with participation from Pender Ventures and Export Development Canada (EDC).
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$15.6M
Headquarters
Ottawa, Canada
Founded
2008
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs